John Lunger
2020
In 2020, John Lunger earned a total compensation of $1.5M as Chief Operating Officer at Adaptimmune Therapeutics, a 59% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $198,000 |
|---|---|
| Option Awards | $857,661 |
| Salary | $400,000 |
| Other | $31,802 |
| Total | $1,487,463 |
Lunger received $857.7K in option awards, accounting for 58% of the total pay in 2020.
Lunger also received $198K in non-equity incentive plan, $400K in salary and $31.8K in other compensation.
Rankings
In 2020, John Lunger's compensation ranked 6,852nd out of 13,090 executives tracked by ExecPay. In other words, Lunger earned more than 47.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,852 out of 13,090 | 48th |
Division Manufacturing | 2,855 out of 5,621 | 49th |
Major group Chemicals And Allied Products | 1,153 out of 2,254 | 49th |
Industry group Drugs | 993 out of 1,954 | 49th |
Industry Biological Products, Except Diagnostic Substances | 239 out of 411 | 42nd |
Source: SEC filing on April 21, 2022.
Lunger's colleagues
We found four more compensation records of executives who worked with John Lunger at Adaptimmune Therapeutics in 2020.